Investor Update Summary

Emerging Market Leader in Asian Pacific Immunogenetics

- TBG is focused in the development of molecular diagnostics in Immunogenetics. Based on our multiplex PCR technology, TBG is developing products for infectious disease diagnostics.

- 9 new distributors with 3 new territories added. Estimated 50% revenue growth in 2018 at 6 Million AUD.

- Key drivers for growth: 1) First to receive China FDA approval for the HLAssure™ SBT Products, 2) Completion of TBG Xiamen clinical reference laboratory and 3) Receiving CE mark for TBG Q6000 Real Time PCR system and ExProbe™ reagents.

- 6 new products in transfusion, autoimmunity and infectious diseases undergoing clinical trials and IVD approval process in 2018.

Company Timeline

Nov 2014
Xiamen plant established

May 2017
Xiamen Lab received ASHI accreditation

Oct 2017
HLAssure™ SBT kit Receives CFDA

Jan 2018
New Distribution Channel for HLAssure™ SBT in China



Feb 2016
TBG Diagnostics Limited listed on ASX as TDL

Jul 2017
ExProbe™ HLA typing kit receives CE Mark

Nov 2017
Q6000 Receives CE mark

May 2018
Xiamen Reference Lab established

Distribution Network

9 New Distributors and 3 New Territories

- Current distribution in over 25 countries worldwide.
- TBG expanded distribution to Albania, Belarus, and Latvia.
- TBG signed with 9 new distributors in China, Albania, Belarus, Latvia, Greece and India.



Revenue Growth in 2018

50% Revenue Growth in 2018

- Until May 2018, China achieved 75% increase in revenue over 2017.
- Major revenue drivers will be CFDA and CE mark product approval.
- Completion of Xiamen TBG reference laboratory will also contribute increase revenue in Q3 and Q4.



- Figures above base on calendar year.
- The figure for 2018 is projected revenue.

New Products Received IVD Certifications

2 Products Lines Received IVD in Q4/2017

TBG HLAssure™ SBT Kit received IVD

- The FIRST to receive China FDA for SBT products.
- HLAssure SE DPB1 Locus SBT kit received CE mark in Q4/2017. DPB typing now recommended for transplantation donor selection.

TBG Q6000 Real Time PCR System CE mark

- Real time PCR is currently the most commonly used platform for IVD testing.
- High level specifications with 6 channel optical system and 96 well format.

New Product and Service Contracts

New Contracts from Portugal, Italy and Turkey

- TBG has obtained contracts for the bone marrow transplant centers in Portugal, Italy and Turkey.

IP ST Instituto Português do Sangue e da Transplantação, IP

- All the contracts are based on the HLAssure™ SBT product line.

- Newly approved HLAssure™ SE DPB1 Locus SBT Kit are now used in Portugal and Italy.

Xiamen Reference Laboratory Completed

Clinical Reference Laboratory Completed in May 2018

Construction complete 5/18/2018 with operational permit issued by June, 2018.

High Standard Gene Testing Facility

First Laboratory in Fujian with High throughput NGS

- Molecular diagnostic laboratory with a comprehensive testing menu.
- ASHI accredited laboratory for Immunogenetics services.
- Testing platform include real time PCR, Luminex, Sanger sequencing, digital PCR and NGS.
- The only laboratory with high throughput NGS for whole genome sequencing in Fujian Province.

Illumina® NovaSeq™

Products and Pipeline

6 New Products Undergoing Clinical Trials and IVD Submission

Product Name	Pilot Production	Clinical Trial Period	IVD Submission
ExProbe B27 Kit	Completed	Q1/2018 to Q3/2018	Q4/2018
ExProbe ABDRDQ	Completed	Q1/2018 to Q1/2019	Q2/2019
ExProbe ABHPA	Q2/2018	Q4/2018 to Q4/2019	Q4/2019
Quant. HBV	Completed	Q2/2018 to Q1/2019	Q2/2019
Quant. HCV	Completed	Q2/2018 to Q1/2019	Q2/2019
GBS	Completed	Q4/2018 to Q4/2019	Q4/2019

Financial Snapshot

Financial Overview from 2016 to 2017

	consolidated	
	6 months ended 31-Dec-16	12 months ended 31-Dec-17
Revenue	1,351,713	4,024,804
Cost of sales	407,796	1,021,658
Gross profit	943,917	3,003,146
other income	346,268	1,181,392
R&D expense	1,476,040	3,039,325
G&A expense	2,158,905	3,926,858
selling expense	460,978	1,078,401
Loss from continuing operations before TAX	(2,805,738)	(3,860,046)
Gain(Loss) from discontinued operations	184,653	(2,687,646)
Net Loss for the year	(2,621,085)	(6,547,692)
Foreign currency translation	309,710	(68,888)
Total COMPREHENSIVE INCOME(LOSS)	(2,311,375)	(6,616,580)
Basic and diluted loss per share-continuing operations(Cents per share)	(1.1)	(1.8)
Basic and diluted loss per share(Cents per share)	(1.2)	(3)

- R&D Tax incentive(A$1.1M in FY2017)
- 1.impaired the deferred payment of PG500 transaction (A$-3M in FY2017)
- 2.Recognized the interest income from the disposal of PharmaSynth (A$0.36M in FY2017)

Disclaimer

This presentation contains forward looking statements that involve risks and uncertainties.

Although we believe that the expectations reflected in the forward looking statements are reasonable at this time, TBG Diagnostics can give no assurance that these expectations will prove to be correct.

Actual results could differ materially from those expected for any of a multitude of risk including, but not limited to, those inherent in regulatory or market environments or more generally. In preparing this presentation, the company has relied upon and assumed, without independent verification, the accuracy and completeness of all information available from public sources, or which was otherwise reviewed by it.

This document does not constitute an offer, solicitation or recommendation in relation to the subscription, purchase or sale of securities in any jurisdiction and does not and will not form of any securities subscription, purchase or sale contract.